Table 1 Characteristics of all the studies included in the meta-analysis
Author | Year | Country | Treatment regimens | Number of patients | Follow-up (months) | Outcomes | ||
|---|---|---|---|---|---|---|---|---|
Experiment | Control | Experiment | Control | |||||
Van Cutsem | 2009 | Belgium | Cetuximab  + FOLFIRI | FOLFIRI | 599 | 599 | Experiment: 29.9 Control: 29.4 | PFS OS ORR R0 resection rate |
Bokemeyer | 2011 | Germany | Cetuximab  + FOLFOX-4 | FOLFOX-4 | 169 | 168 | NA | PFS OS ORR R0 resection rate |
Maughan | 2011 | England | Oxaliplatin and fluoropyrimidine + cetuximab | Oxaliplatin and fluoropyrimidine | 815 | 815 | Experiment: 78 Control: 76 | PFS OS ORR R0 resection rate |
Tveit | 2012 | Norway | Cetuximab  + Nordic FLOX | Nordic FLOX | 194 | 185 | NA | PFS OS ORR R0 resection rate |
Ye | 2013 | China | Cetuximab  + FOLFIRI or mFOLFOX6 | FOLFIRI or mFOLFOX6 | 70 | 68 | 25.0 | PFS OS ORR R0 resection rate |
Qin | 2018 | China | Cetuximab + FOLFOX-4 | FOLFOX-4 | 193 | 200 | Experiment: 44.4 Control: 48.7 | PFS OS ORR R0 resection rate |
Modest | 2019 | Germany | Panitumumab  + mFOLFOXIRI | mFOLFOXIRI | 63 | 33 | Experiment: 44.2 Control: 66.3 | PFS OS ORR R0 resection rate |
Douillard | 2014 | France | Panitumumab  + FOLFOX4 | FOLFOX4 | 546 | 550 | Experiment: 15.3 Control: 18.5 | PFS OS ORR R0 resection rate |